デフォルト表紙
市場調査レポート
商品コード
1301134

ガンマナイフの市場規模、シェア、動向分析レポート:適応症別、地域別、セグメント予測、2023年~2030年

Gamma Knife Market Size, Share & Trends Analysis Report By Indication (Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders, Ocular Diseases), By Region, And Segment Forecasts, 2023 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 105 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
ガンマナイフの市場規模、シェア、動向分析レポート:適応症別、地域別、セグメント予測、2023年~2030年
出版日: 2023年06月26日
発行: Grand View Research
ページ情報: 英文 105 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ガンマナイフ市場の成長と動向

GrandView Research, Inc.の最新レポートによると、ガンマナイフの世界市場規模は2030年までに6億2,640万米ドルに達すると予測されています。

2023年から2030年までのCAGRは5.0%で成長すると予測されています。がん、脳腫瘍、その他の神経疾患の有病率の増加、手術センターにおけるこれらの器具の採用の増加、低侵襲手術(MIS)への嗜好の高まり、器具の技術的進歩などは、市場を牽引すると予想されるいくつかの要因の一つです。

ガンマナイフ療法は、脳腫瘍、脳転移、てんかん、動静脈奇形など、さまざまな脳・神経疾患の治療に用いられます。安全性、微小精度、術後合併症の少なさ、切開の少なさなどさまざまな利点があるため、手術センターでの需要が伸びています。

技術の進歩により、手術の精度は向上しています。例えば、Leksell Gamma KnifeのモデルU、B、C/4C、PerfexionがIconにアップグレードされたことで、手術における微小精度が向上し、手術センターでのこの装置の採用が後押しされました。Elekta ABが発表した報告書によると、毎年約7万人の患者がガンマナイフ手術を受けています。この数は、対象疾患の有病率の上昇とMISへの嗜好の高まりにより、予測期間中に増加すると予想されています。

さらに、開腹手術よりもMISに対する需要が高まっていることも、この治療法の採用を増加させている主な要因の1つです。ガンマナイフ治療法は、開腹手術に比べて外傷が少なく、回復も早いです。在院日数が短縮されるため、経済的な生存可能性が確保され、医療費が削減されます。切開や術後の合併症が少ないことが、低侵襲手術の需要を押し上げる主な要因となっています。

ガンマナイフ市場レポートハイライト

  • 2022年、悪性腫瘍が最大の適応症として浮上機能障害分野は予測期間中に最も速い成長が見込まれる
  • がんの罹患率上昇、ヘルスケアインフラの発展、新興経済諸国の急速な経済発展により、アジア太平洋地域が2022年に最大の売上シェアを獲得
  • ガンマナイフは同社の特許製品であるため、この市場で事業を展開しているのはElekta ABのみです。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
    • 製品
    • 針の長さ
    • 治療
    • 地域範囲
    • 推定・予測のタイムライン
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • GVRの内部データベース
    • 二次情報
    • 1次調査
    • 1次調査の詳細
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の形成と検証
  • モデル詳細
    • 商品フロー解析(モデル1)
    • 出来高価格分析(モデル2)
  • 二次情報のリスト
  • 一次情報のリスト
  • 目的

第2章 エグゼクティブサマリー

  • 市場スナップショット
  • セグメントのスナップショット
  • 競合のスナップショット

第3章 ガンマナイフの市場変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • ガンマナイフ市場分析ツール
    • 業界分析- ポーターの分析
    • PESTEL分析
    • 主要取引と戦略的提携の分析
    • 市場参入戦略

第4章 ガンマナイフ市場:推定・動向分析

  • 適応症の市場シェア、2022年および2030年
  • セグメントダッシュボード
  • 適応症別の世界のガンマナイフ市場の見通し
  • 以下の市場規模、予測および動向分析、2018年から2030年まで
    • 悪性腫瘍
    • 良性腫瘍
    • 血管障害
    • 機能障害
    • 眼科

第5章 ガンマナイフ市場:地域推定・動向分析

  • 地域市場シェア分析、2022年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 地域市場シェアと主要企業、2022年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東とアフリカ
  • 2018年から2030年の市場用途、予測および動向分析
  • 北米
    • 市場推計・予測、2018~2030年(収益)
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • インド
    • 中国
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • MEA
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
    • イノベーター
  • ベンダー情勢
    • 主なディストリビューターとチャネルパートナーのリスト
    • 主な顧客
    • 主要企業の市場シェア分析、2022年
    • Elekta AB
    • Huiheng Medical, Inc.
    • MASEP Medical Science Technology Development(Shenzhen)Co., Ltd.
    • Akesis Inc.
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Gamma Knife market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 4 U.S. Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 5 Canada Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 6 Europe Gamma Knife market, by region, 2018 - 2030 (USD Million)
  • Table 7 Europe Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.K. Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 9 Germany Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 10 France Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Italy Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Spain Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Denmark Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Sweden Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Norway Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific Gamma Knife market, by region, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Japan Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 19 China Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 20 India Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Australia Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 22 Thailand Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 23 South Korea Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Latin America Gamma Knife market, by region, 2018 - 2030 (USD Million)
  • Table 25 Latin America Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Brazil Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Mexico Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Argentina Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa Gamma Knife market, by region, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 31 South Africa Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 33 UAE Gamma Knife market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Kuwait Gamma Knife market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Gamma Knife market: market outlook
  • Fig. 14 Gamma Knife market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Gamma Knife market driver impact
  • Fig. 18 Gamma Knife market restraint impact
  • Fig. 19 Gamma Knife market strategic initiatives analysis
  • Fig. 20 Gamma Knife market: Indication movement analysis
  • Fig. 21 Gamma Knife market: Indication outlook and key takeaways
  • Fig. 22 Malignant tumors market estimates and forecast, 2018 - 2030
  • Fig. 23 Benign tumors market estimates and forecast, 2018 - 2030
  • Fig. 24 Vascular disorders market estimates and forecast, 2018 - 2030
  • Fig. 25 Functional disorders therapy market estimates and forecast, 2018 - 2030
  • Fig. 26 Ocular market estimates and forecast, 2018 - 2030
  • Fig. 27 Global Gamma Knife market: Regional movement analysis
  • Fig. 28 Global Gamma Knife market: Regional outlook and key takeaways
  • Fig. 29 Global market shares and leading players
  • Fig. 30 North America market share and leading players
  • Fig. 31 Europe market share and leading players
  • Fig. 32 Asia Pacific market share and leading players
  • Fig. 33 Latin America market share and leading players
  • Fig. 34 Middle East & Africa market share and leading players
  • Fig. 35 North America: SWOT
  • Fig. 36 Europe SWOT
  • Fig. 37 Asia Pacific SWOT
  • Fig. 38 Latin America SWOT
  • Fig. 39 MEA SWOT
  • Fig. 40 North America, by country
  • Fig. 41 North America
  • Fig. 42 North America market estimates and forecast, 2018 - 2030
  • Fig. 43 U.S.
  • Fig. 44 U.S. market estimates and forecast, 2018 - 2030
  • Fig. 45 Canada
  • Fig. 46 Canada market estimates and forecast, 2018 - 2030
  • Fig. 47 Europe
  • Fig. 48 Europe. market estimates and forecast, 2018 - 2030
  • Fig. 49 U.K.
  • Fig. 50 U.K. market estimates and forecast, 2018 - 2030
  • Fig. 51 Germany
  • Fig. 52 Germany market estimates and forecast, 2018 - 2030
  • Fig. 53 France
  • Fig. 54 France market estimates and forecast, 2018 - 2030
  • Fig. 55 Italy
  • Fig. 56 Italy market estimates and forecast, 2018 - 2030
  • Fig. 57 Spain
  • Fig. 58 Spain market estimates and forecast, 2018 - 2030
  • Fig. 59 Denmark
  • Fig. 60 Denmark market estimates and forecast, 2018 - 2030
  • Fig. 61 Sweden
  • Fig. 62 Sweden market estimates and forecast, 2018 - 2030
  • Fig. 63 Norway
  • Fig. 64 Norway market estimates and forecast, 2018 - 2030
  • Fig. 65 Asia Pacific
  • Fig. 66 Asia Pacific market estimates and forecast, 2018 - 2030
  • Fig. 67 Japan
  • Fig. 68 Japan market estimates and forecast, 2018 - 2030
  • Fig. 69 China
  • Fig. 70 China market estimates and forecast, 2018 - 2030
  • Fig. 71 India
  • Fig. 72 India market estimates and forecast, 2018 - 2030
  • Fig. 73 Australia
  • Fig. 74 Australia market estimates and forecast, 2018 - 2030
  • Fig. 75 Thailand
  • Fig. 76 Thailand market estimates and forecast, 2018 - 2030
  • Fig. 77 South Korea
  • Fig. 78 South Korea market estimates and forecast, 2018 - 2030
  • Fig. 79 Latin America
  • Fig. 80 Latin America market estimates and forecast, 2018 - 2030
  • Fig. 81 Brazil
  • Fig. 82 Brazil market estimates and forecast, 2018 - 2030
  • Fig. 83 Mexico
  • Fig. 84 Mexico market estimates and forecast, 2018 - 2030
  • Fig. 85 Argentina
  • Fig. 86 Argentina market estimates and forecast, 2018 - 2030
  • Fig. 87 Middle East and Africa
  • Fig. 88 Middle East and Africa market estimates and forecast, 2018 - 2030
  • Fig. 89 Saudi Arabia
  • Fig. 90 Saudi Arabia market estimates and forecast, 2018 - 2030
  • Fig. 91 South Africa
  • Fig. 92 South Africa market estimates and forecast, 2018 - 2030
  • Fig. 93 UAE
  • Fig. 94 UAE market estimates and forecast, 2018 - 2030
  • Fig. 95 Kuwait
  • Fig. 96 Kuwait market estimates and forecast, 2018 - 2030
  • Fig. 97 Participant categorization - Gamma Knife market
  • Fig. 98 Market share of key market players - Gamma Knife market
目次
Product Code: GVR-1-68038-581-6

Gamma Knife Market Growth & Trends

The global gamma knife market size is expected to reach USD 626.4 million by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 5.0% from 2023 to 2030. The increasing prevalence of cancer, brain tumors, and other neurological diseases, rising adoption of these instruments in surgery centers, growing preference for Minimally Invasive Surgeries (MIS), and technological advancements in the device are among few factors expected to drive the market.

Gamma knife therapy is used for the treatment of various brain and neurological disorders such as brain tumors, brain metastases, epilepsy, and arteriovenous malformations. Demand for these instruments in surgery centers is growing due to their various advantages such as safety, micro-precision, lack of postsurgical complications, and lack of incisions.

Technological advancements have improved precision in surgery. For instance, the up-gradation of Leksell Gamma Knife models U, B, C/4C, and Perfexion to Icon provided micro-precision in surgery and boosted the adoption of this device in surgery centers. According to reports published by Elekta AB, approximately 70,000 patients undergo gamma knife surgery each year. This number is expected to increase over the forecast period owing to the rising prevalence of target diseases and increasing preference for MIS.

In addition, the growing demand for MIS over open surgeries is one of the key factors responsible for increasing the adoption of this therapy. Gamma knife treatment procedure results in fewer traumas and faster recovery as compared to open surgeries. It helps reduce hospital stays, thus ensuring economic viability and reduction in medical expenses. Lack of incisions and post-surgical complications are key factors responsible for boosting the demand for minimally invasive surgeries.

Gamma Knife Market Report Highlights

  • Malignant tumors emerged as the largest indication segment in 2022. The functional disorders segment is anticipated to witness the fastest growth over the forecast period
  • The Asia Pacific held the largest revenue share in 2022 owing to the rising incidence of cancer, developments in healthcare infrastructure, and rapid economic development across major emerging economies
  • Elekta AB is the only player operating in this market since Gamma Knife is a patent-protected trademark product of the company

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Needle Length
    • 1.1.3. Therapy
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Snapshot

Chapter 3. Gamma knife Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Gamma knife Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape
    • 3.4.3. Major Deals & Strategic Alliances Analysis
    • 3.4.4. Market Entry Strategies

Chapter 4. Gamma Knife Market: Indication Estimates & Trend Analysis

  • 4.1. Indication Market Share, 2022 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Gamma Knife Market by Indication Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Malignant Tumors
      • 4.4.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.2. Benign Tumors
      • 4.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.3. Vascular Disorders
      • 4.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.4. Functional Disorders
      • 4.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.5. Ocular
      • 4.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Gamma Knife Market: Regional Estimates & Trend Analysis

  • 5.1. Regional market share analysis, 2022 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Regional Market Share and Leading Players, 2022
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East and Africa
  • 5.5. Market Application, & Forecasts and Trend Analysis, 2018 to 2030
  • 5.6. North America
    • 5.6.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. U.S.
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory framework
      • 5.6.2.4. Reimbursement scenario
      • 5.6.2.5. U.S. market estimates and forecasts, 2018 - 2030
    • 5.6.3. Canada
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory framework
      • 5.6.3.4. Reimbursement scenario
      • 5.6.3.5. Canada market estimates and forecasts, 2018 - 2030
  • 5.7. Europe
    • 5.7.1. UK
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory framework
      • 5.7.1.4. Reimbursement scenario
      • 5.7.1.5. UK market estimates and forecasts, 2018 - 2030
    • 5.7.2. Germany
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory framework
      • 5.7.2.4. Reimbursement scenario
      • 5.7.2.5. Germany market estimates and forecasts, 2018 - 2030
    • 5.7.3. France
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Competitive Scenario
      • 5.7.3.3. Regulatory framework
      • 5.7.3.4. Reimbursement scenario
      • 5.7.3.5. France market estimates and forecasts, 2018 - 2030
    • 5.7.4. Italy
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Competitive Scenario
      • 5.7.4.3. Regulatory framework
      • 5.7.4.4. Reimbursement scenario
      • 5.7.4.5. Italy market estimates and forecasts, 2018 - 2030
    • 5.7.5. Spain
      • 5.7.5.1. Key country dynamics
      • 5.7.5.2. Competitive Scenario
      • 5.7.5.3. Regulatory framework
      • 5.7.5.4. Reimbursement scenario
      • 5.7.5.5. Spain market estimates and forecasts, 2018 - 2030
    • 5.7.6. Denmark
      • 5.7.6.1. Key country dynamics
      • 5.7.6.2. Competitive Scenario
      • 5.7.6.3. Regulatory framework
      • 5.7.6.4. Reimbursement scenario
      • 5.7.6.5. Denmark market estimates and forecasts, 2018 - 2030
    • 5.7.7. Sweden
      • 5.7.7.1. Key country dynamics
      • 5.7.7.2. Competitive Scenario
      • 5.7.7.3. Regulatory framework
      • 5.7.7.4. Reimbursement scenario
      • 5.7.7.5. Market estimates and forecasts, 2018 - 2030
    • 5.7.8. Norway
      • 5.7.8.1. Key country dynamics
      • 5.7.8.2. Competitive Scenario
      • 5.7.8.3. Regulatory framework
      • 5.7.8.4. Reimbursement scenario
      • 5.7.8.5. Norway market estimates and forecasts, 2018 - 2030
  • 5.8. Asia Pacific
    • 5.8.1. Japan
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory framework
      • 5.8.1.4. Reimbursement scenario
      • 5.8.1.5. Japan market estimates and forecasts, 2018 - 2030
    • 5.8.2. India
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory framework
      • 5.8.2.4. Reimbursement scenario
      • 5.8.2.5. India market estimates and forecasts, 2018 - 2030
    • 5.8.3. China
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory framework
      • 5.8.3.4. Reimbursement scenario
      • 5.8.3.5. China market estimates and forecasts, 2018 - 2030
    • 5.8.4. South Korea
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Competitive Scenario
      • 5.8.4.3. Regulatory framework
      • 5.8.4.4. Reimbursement scenario
      • 5.8.4.5. South Korea market estimates and forecasts, 2018 - 2030
    • 5.8.5. Australia
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Competitive Scenario
      • 5.8.5.3. Regulatory framework
      • 5.8.5.4. Reimbursement scenario
      • 5.8.5.5. Australia market estimates and forecasts, 2018 - 2030
    • 5.8.6. Thailand
      • 5.8.6.1. Key country dynamics
      • 5.8.6.2. Competitive Scenario
      • 5.8.6.3. Regulatory framework
      • 5.8.6.4. Reimbursement scenario
      • 5.8.6.5. Thailand market estimates and forecasts, 2018 - 2030
  • 5.9. Latin America
    • 5.9.1. Brazil
      • 5.9.1.1. Key country dynamics
      • 5.9.1.2. Competitive Scenario
      • 5.9.1.3. Regulatory framework
      • 5.9.1.4. Reimbursement scenario
      • 5.9.1.5. Brazil market estimates and forecasts, 2018 - 2030
    • 5.9.2. Mexico
      • 5.9.2.1. Key country dynamics
      • 5.9.2.2. Competitive Scenario
      • 5.9.2.3. Regulatory framework
      • 5.9.2.4. Reimbursement scenario
      • 5.9.2.5. Mexico market estimates and forecasts, 2018 - 2030
    • 5.9.3. Argentina
      • 5.9.3.1. Key country dynamics
      • 5.9.3.2. Competitive Scenario
      • 5.9.3.3. Regulatory framework
      • 5.9.3.4. Reimbursement scenario
      • 5.9.3.5. Argentina market estimates and forecasts, 2018 - 2030
  • 5.10. MEA
    • 5.10.1. South Africa
      • 5.10.1.1. Key country dynamics
      • 5.10.1.2. Competitive Scenario
      • 5.10.1.3. Regulatory framework
      • 5.10.1.4. Reimbursement scenario
      • 5.10.1.5. South Africa market estimates and forecasts, 2018 - 2030
    • 5.10.2. Saudi Arabia
      • 5.10.2.1. Key country dynamics
      • 5.10.2.2. Competitive Scenario
      • 5.10.2.3. Regulatory framework
      • 5.10.2.4. Reimbursement scenario
      • 5.10.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
    • 5.10.3. UAE
      • 5.10.3.1. Key country dynamics
      • 5.10.3.2. Competitive Scenario
      • 5.10.3.3. Regulatory framework
      • 5.10.3.4. Reimbursement scenario
      • 5.10.3.5. UAE market estimates and forecasts, 2018 - 2030
    • 5.10.4. Kuwait
      • 5.10.4.1. Key country dynamics
      • 5.10.4.2. Competitive Scenario
      • 5.10.4.3. Regulatory framework
      • 5.10.4.4. Reimbursement scenario
      • 5.10.4.5. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
    • 6.2.1. Innovators
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2022
    • 6.3.4. Elekta AB
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Huiheng Medical, Inc.
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Akesis Inc.
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives